Isolation, identification and excretion profile of the principal urinary metabolite of the recently banned designer drug 1-(3-trifluoromethylphenyl)piperazine (TFMPP) in rats

By Tsutsumi H   Katagi M   Miki A.   Shima N   Kamata T   Nakajima K.   Inoue H   Kishi T   Tsuchihashi H  

Xenobiotica, Vol. 35, Iss. 1, 2005-01 ,pp. : 107-116

Informa Healthcare

Access to resources Recommend Favorite

Metabolism of the antineoplastic and immunosuppressive drug 2-CdA (Leustatin®) in animals and humans

By Wu W. N.   Mckown L. A.   Moyer M. D.   Cheung W.  

Xenobiotica, Vol. 34, Iss. 6, 2004-06 ,pp. : 591-606

Informa Healthcare

Access to resources Recommend Favorite

Metabolism and urinary excretion of a new quinoline anticancer drug, TAS-103, in humans

By Azuma R.   Saeki M.   Yamamoto Y.   Hagiwara Y.   Grochow L. B.   Donehower R. C.  

Xenobiotica, Vol. 32, Iss. 1, 2002-01 ,pp. : 63-72

Informa Healthcare

Access to resources Recommend Favorite

Identification of cytochrome P450 enzymes involved in the metabolism of 3',4'-methylenedioxy- a -pyrrolidinopropiophenone (MDPPP), a designer drug, in human liver microsomes

By Springer D   Staack R. F   Paul L. D   Kraemer T   Maurer H. H  

Xenobiotica, Vol. 35, Iss. 3, 2005-03 ,pp. : 227-237

Informa Healthcare

Access to resources Recommend Favorite

Identification of cytochrome P450 enzymes involved in the metabolism of 4′-methoxy--pyrrolidinopropiophenone (MOPPP), a designer drug, in human liver microsomes

By Springer D.   Staack R. F.   Paul L. D.   Kraemer T.   Maurer H. H.  

Xenobiotica, Vol. 33, Iss. 10, 2003-10 ,pp. : 989-998

Informa Healthcare

Access to resources Recommend Favorite